Halozyme's 36% Surge: Momentum or Overreach?

What happened

Halozyme shares surged 36% over the past month, driven by robust ENHANZE royalty growth and management's upward revision to 2026 guidance. The company's royalty platform is delivering strong results, with ten commercial products and growing adoption of subcutaneous biologics. However, this positive news must be weighed against structural risks highlighted in our prior analysis, including the 2027 patent cliff on core ENHANZE IP, high partner concentration, and a leveraged balance sheet with significant debt maturities in 2027-2028. The stock's valuation, previously ~33% above our DCF estimate, has now stretched further as the price increase has outpaced likely revisions to intrinsic value. While the raised guidance signals near-term momentum, it does not resolve the medium-term challenges that underpinned our WAIT rating.

Implication

The 36% monthly gain reflects market enthusiasm for raised guidance, but it also elevates the bar for future performance. While ENHANZE royalties are growing impressively, the patent expiries beginning in 2027 could erode the core business just as debt maturities peak. The recent M&A activity (Antares, Elektrofi, potential Evotec) adds integration risk that is not yet proven. A value-oriented approach would require either a meaningful pullback toward our DCF estimate or clear evidence that new platforms and IP extensions can sustain cash flows beyond 2030. Until then, the risk/reward remains skewed to the downside, and we would not chase the rally.

Thesis delta

The raised 2026 guidance supports our view that ENHANZE's near-term royalty momentum is strong, but it does not alter our medium-term concerns about IP expiry and leverage. Consequently, we maintain our WAIT stance, though we acknowledge that if the raised guidance is substantiated by sustained cash flow growth, the intrinsic value may be higher than our previous estimate. We will monitor upcoming royalty reports and debt refinancing actions for evidence of a durable improvement.